Immix soars as it in-licenses next-gen CAR-T therapy

16 December 2022

USA-based Immix Biopharma (Nasdaq: IMMX), which is pioneering tissue-specific therapeutics (TSTx) targeting oncology and immuno-dysregulated diseases, saw its shares leap more than 41% to $2.07, after it announced a licensing deal and the formation of a new subsidiary.

Immix has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly HBI0101) with 85% overall response rate (ORR) and 71% complete response/stringent complete response (CR/sCR) at the therapeutic dose from the first 20 patients in an ongoing Phase Ib relapsed/refractory multiple myeloma ongoing clinical trial as of June 27, 2022 data cut-off with a median of 6 (range, 3-13) prior lines of therapy.

Immix did not reveal from whom it had licensed the product, nor any financial terms of the transaction.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK